# Government caps trade margins on all non-scheduled anti-cancer drugs at 30% 2026-10-08T11:52:18+00:00 | Governance | Indian Opinion Desk Corroboration: 2 independent outlets The government on Thursday, 8 October 2026, capped trade margins at 30% of MRP on all non-scheduled anti-cancer drugs, covering branded, generic, domestic and imported medicines. Official sources cited by ANI said the measure could cut MRP by up to 70%, saving patients an estimated Rs 2,500 crore annually. Union Health Minister JP Nadda is expected to announce the expanded list, days before the Supreme Court hears the matter on 12 October. The decision extends a 2019 policy that capped margins on 42 drugs and saved Rs 984 crore across 526 brands. The Department of Pharmaceuticals analysed trade margins after court observations on the gap between price to retailer and MRP. An industry expert cautioned that the PTR-MRP gap reflects distribution, storage and handling costs, and urged assessment of the full supply chain. ## Indian Opinion Analysis Economic Times frames the announcement as a government response to Supreme Court pressure and names an October 12 hearing as the deadline, while Times of India reports the cap as a standalone affordability measure projected to save patients Rs 2,500 crore annually. ET includes an industry expert’s caveat that the PTR-MRP gap reflects supply chain costs, a detail TOI omits. TOI sources the decision solely to official sources via ANI and foregrounds the 70% price reduction estimate. Both outlets present the policy as given, with no opposition or critical framing. The uniform coverage is straight reporting, the key difference is ET’s inclusion of the court context and industry pushback, which together suggest the cap is a preemptive compliance action, not a purely executive initiative. The Supreme Court hearing on 12 October will test whether the list satisfies the court’s concerns. ## Coverage Coverage: 2 sources, 2 neutral - economictimes.indiatimes.com (neutral report) Leads with SC deadline, includes industry expert caution - timesofindia.indiatimes.com (neutral report) Leads with affordability and Rs 2,500 crore savings estimate This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Tags: Department of Pharmaceuticals, JP Nadda, NPPA, PMO, Supreme Court Canonical: https://indianopinion.org/government-caps-trade-margins-on-all-non-scheduled-anti-cancer-drugs-at-30/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/government-caps-trade-margins-on-all-non-scheduled-anti-cancer-drugs-at-30/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/